Estado actual de la terapia con células madre en el tratamiento de las cardiopatías

Available medical therapy is unable to completely prevent or revert the pathological cardiac remodeling secondary to ischemia or other injuries, which is responsible for the development of heart failure. Regenerative medicine through stem cells had an explosive development in the cardiovascular area...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Bartolucci,Jorge, Verdugo,Fernando J, Larrea,Ricardo, Carrión,Flavio, Lamich,Rubén, Pedreros,Pablo, Delgado,Manuel, Sanhueza,Patricio, Khoury,Maroun, Figueroa,Fernando E
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2014
Materias:	Cardiomyopathies Myocardial Infaction Stem Cell Transplantation Ventricular Remodeling
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872014000800011
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872014000800011
record_format	dspace
spelling	oai:scielo:S0034-988720140008000112014-12-12Estado actual de la terapia con células madre en el tratamiento de las cardiopatíasBartolucci,JorgeVerdugo,Fernando JLarrea,RicardoCarrión,FlavioLamich,RubénPedreros,PabloDelgado,ManuelSanhueza,PatricioKhoury,MarounFigueroa,Fernando E Cardiomyopathies Myocardial Infaction Stem Cell Transplantation Ventricular Remodeling Available medical therapy is unable to completely prevent or revert the pathological cardiac remodeling secondary to ischemia or other injuries, which is responsible for the development of heart failure. Regenerative medicine through stem cells had an explosive development in the cardiovascular area during the past decade. Stem cells possess the capacity to regenerate, repair or substitute damaged tissue, allowing the reestablishment of its function. Stem cells can also modulate apoptosis, angiogenesis, fibrosis and inflammation, favoring the endogenous regenerative process initiated by the damaged tissue. These capacities have been corroborated in several animal models of cardiovascular diseases with positive results. In humans, therapies with bone marrow mononuclear stem cells, mesenchymal stem cells and cardiac stem cells are safe. Most randomized clinical trials in patients with myocardial infarction or cardiomyopathies of different etiologies have reported benefits on ventricular function, quality of life and even over mortality of treated patients. This article reviews the state of art of stem cell therapy in cardiovascular diseases, focusing on the most common cellular types used in patients with acute myocardial infarction and chronic cardiomyopathies of different etiologies.info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.142 n.8 20142014-08-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872014000800011es10.4067/S0034-98872014000800011
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Cardiomyopathies Myocardial Infaction Stem Cell Transplantation Ventricular Remodeling
spellingShingle	Cardiomyopathies Myocardial Infaction Stem Cell Transplantation Ventricular Remodeling Bartolucci,Jorge Verdugo,Fernando J Larrea,Ricardo Carrión,Flavio Lamich,Rubén Pedreros,Pablo Delgado,Manuel Sanhueza,Patricio Khoury,Maroun Figueroa,Fernando E Estado actual de la terapia con células madre en el tratamiento de las cardiopatías
description	Available medical therapy is unable to completely prevent or revert the pathological cardiac remodeling secondary to ischemia or other injuries, which is responsible for the development of heart failure. Regenerative medicine through stem cells had an explosive development in the cardiovascular area during the past decade. Stem cells possess the capacity to regenerate, repair or substitute damaged tissue, allowing the reestablishment of its function. Stem cells can also modulate apoptosis, angiogenesis, fibrosis and inflammation, favoring the endogenous regenerative process initiated by the damaged tissue. These capacities have been corroborated in several animal models of cardiovascular diseases with positive results. In humans, therapies with bone marrow mononuclear stem cells, mesenchymal stem cells and cardiac stem cells are safe. Most randomized clinical trials in patients with myocardial infarction or cardiomyopathies of different etiologies have reported benefits on ventricular function, quality of life and even over mortality of treated patients. This article reviews the state of art of stem cell therapy in cardiovascular diseases, focusing on the most common cellular types used in patients with acute myocardial infarction and chronic cardiomyopathies of different etiologies.
author	Bartolucci,Jorge Verdugo,Fernando J Larrea,Ricardo Carrión,Flavio Lamich,Rubén Pedreros,Pablo Delgado,Manuel Sanhueza,Patricio Khoury,Maroun Figueroa,Fernando E
author_facet	Bartolucci,Jorge Verdugo,Fernando J Larrea,Ricardo Carrión,Flavio Lamich,Rubén Pedreros,Pablo Delgado,Manuel Sanhueza,Patricio Khoury,Maroun Figueroa,Fernando E
author_sort	Bartolucci,Jorge
title	Estado actual de la terapia con células madre en el tratamiento de las cardiopatías
title_short	Estado actual de la terapia con células madre en el tratamiento de las cardiopatías
title_full	Estado actual de la terapia con células madre en el tratamiento de las cardiopatías
title_fullStr	Estado actual de la terapia con células madre en el tratamiento de las cardiopatías
title_full_unstemmed	Estado actual de la terapia con células madre en el tratamiento de las cardiopatías
title_sort	estado actual de la terapia con células madre en el tratamiento de las cardiopatías
publisher	Sociedad Médica de Santiago
publishDate	2014
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872014000800011
work_keys_str_mv	AT bartoluccijorge estadoactualdelaterapiaconcelulasmadreeneltratamientodelascardiopatias AT verdugofernandoj estadoactualdelaterapiaconcelulasmadreeneltratamientodelascardiopatias AT larrearicardo estadoactualdelaterapiaconcelulasmadreeneltratamientodelascardiopatias AT carrionflavio estadoactualdelaterapiaconcelulasmadreeneltratamientodelascardiopatias AT lamichruben estadoactualdelaterapiaconcelulasmadreeneltratamientodelascardiopatias AT pedrerospablo estadoactualdelaterapiaconcelulasmadreeneltratamientodelascardiopatias AT delgadomanuel estadoactualdelaterapiaconcelulasmadreeneltratamientodelascardiopatias AT sanhuezapatricio estadoactualdelaterapiaconcelulasmadreeneltratamientodelascardiopatias AT khourymaroun estadoactualdelaterapiaconcelulasmadreeneltratamientodelascardiopatias AT figueroafernandoe estadoactualdelaterapiaconcelulasmadreeneltratamientodelascardiopatias
_version_	1718436772469276672

Estado actual de la terapia con células madre en el tratamiento de las cardiopatías

Ejemplares similares